

132. (Amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor-like domain comprises an [the] amino acid sequence [of] which is identical to an amino acid sequence encoded by a GGF/p185 erb B2 ligand gene, and wherein said amino acid sequence comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of:

SEQ ID NO: 154 (EGFL1);

SEQ ID NO: 155 (EGFL2);

SEQ ID NO: 156 (EGFL3);

SEQ ID NO: 157 (EGFL4);

SEQ ID NO: 158 (EGFL5);

SEQ ID NO: 159 (EGFL6); and

amino acids 54-103 encoded by SEQ ID NO: 150

[sufficient to induce myelination of a neural cell by said glial cell].

136. (Amended) [The method of claim 133] A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain,

136. (Twice amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth [factor like] factor-like domain comprises the [polypeptide encoded by] amino acid sequence set forth in SEQ ID NO: 188[, wherein the human C/D'-segment polypeptide encoded by SEQ ID NO: 179 is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177].

N
A

137. (Twice amended) A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth [factor like] factor-like domain comprises the [polypeptide encoded by] amino acid sequence set forth in SEQ ID NO: 189[, wherein the bovine C/D'-segment polypeptide encoded by SEQ ID NO: 143 is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177, and the human D-segment polypeptide encoded by SEQ ID NO: 180 is immediately C-terminal to the polypeptide encoded by SEQ ID NO: 143].

In the Drawings:

Replace Figs. 31I-31L with the corrected copies of Figs. 31I-31L, provided herewith.

wherein said epidermal growth factor like domain [further] comprises the polypeptide encoded by SEQ ID NO: 188, wherein the human C/D'-segment polypeptide encoded by SEQ ID NO: 179 [178] [, wherein SEQ ID NO: 178] is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177.

Sub D29 cont
C7

137. (Amended) [The method of claim 133] A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor like domain [further] comprises the polypeptide encoded by SEQ ID NO: 189 [SEQ ID NO: 179], wherein the bovine C/D' -segment polypeptide encoded by SEQ ID NO: 143 [42] is immediately C-terminal to the human C-segment polypeptide encoded by SEQ ID NO: 177, and the human D-segment polypeptide encoded by SEQ ID NO: 180 is immediately C-terminal to the polypeptide encoded by SEQ ID NO: 143.

139. (Amended) The method of claim 132, 136, 137 or 141, wherein said [A] method [for inducing myelination of a neural cell by a glial cell,] further [comprising] comprises contacting said cell with [an amount of] a polypeptide which binds the p185 erb B2 receptor[, sufficient to induce myelination of a neural cell by said glial cell].

C¹ 140. (Amended) The method of claim 132, 136, 137 or 141, wherein said polypeptide is [A method of inducing myelination of a neural cell by a glial cell, comprising contacting said glial cell with an amount of] a recombinant polypeptide with glial cell mitogenic activity [sufficient to induce myelination of a neural cell by said glial cell].

Add new claims 141-143.

C⁸ --141. A method for inducing myelination of a neural cell by a glial cell, said method comprising contacting said glial cell with an amount of a polypeptide which comprises an epidermal growth factor-like domain, wherein said epidermal growth factor-like domain comprises an amino acid sequence which is identical to an amino acid sequence encoded by a GGF/p185 erb B2 ligand gene, and wherein said amino acid sequence is selected from the group consisting of:

SEQ ID NO: 151;

SEQ ID NO: 152; and

amino acids 362-411 of SEQ ID NO: 170,

wherein said contacting with said polypeptide is sufficient to induce myelination of said neural cell by said glial cell.



PATENT
ATTORNEY DOCKET NO. 04585/002000

1647
#22E/HW
02-12-02

Certificate of Mailing: Date of Deposit: <u>January 17, 2002</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Roselynn D. Scarfo</u> Printed name of person mailing correspondence	<u>Roselynn D. Scarfo</u> Signature of person mailing correspondence

TECH CENTER 1600/2900

RECEIVED
FEB 05 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Goodearl et al.	Art Unit:	1647
Serial No.:	08/736,019	Examiner:	Gucker, S.
Filed:	October 22, 1996	Customer No.:	21559
Title:	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE		

Assistant Commissioner for Patents
Washington, D.C. 20231

REPLY TO EXAMINER'S ACTION

In reply to the Examiner's Action mailed in the above-captioned case on October 29, 2001, Applicants submit the following amendments and remarks.

AMENDMENTS

In the claims

Please amend claims 142 and 143 to read as follows:

142. (Amended) The method of claim 141, wherein said amino acid sequence is SEQ ID

NO: 151.

E1

143. (Amended) The method of claim 141, wherein said amino acid sequence is SEQ ID

NO: 152.
